Gapping up
In reaction to earnings/guidance: PEP +2.3%, WBA +2.3%, AA +1.2%, COST +1.2%, (June SSS)
M&A news: MM +26.9% (TechCrunch report suggesting Verizon (VZ) might be considering acquisition of MM), YY +7.1% ("Going Private" Proposal for $68.50/ADS), AVP +1.7% (reports its divestiture of Liz Earle for £140 million in cash)
Select China related names showing strength: SHI +18.1%, AMCN +15.6%, WBAI +14.9%, NQ +14.5%, BZUN +12.4%, LTBR +11.5%, NOAH +11.5%, EJ +11.5%, JMEI +11%, CMCM +10.2%, YOKU +10.1%, XNET +9.9%, QIHU +9%, DANG +8.8%, VISN +8.1%, SINA +7.9%, SOHU +7.3%, JRJC +6.9%, WUBA +6.1%, JD +5.9%, CTRP +5.3%, LFC +4.4%, BIDU+3.4%
Select EU bank stocks trading higher: ING +4.1%, DB +3.1%, NBG +2.9%, HSBC +2.4%, CS +2.2%, BCS +2%
Select solar names showing early strength: SOL +8.7%, JASO +8.2%, JKS +6.9%, TSL +6.1%, YGE +5.3%
Other news: RMGN +35.3% (announces the signing of a multimillion agreement; Initial purchases under the award total $1.1 mln), IPCI +12.7% (announced the FDA rescinds previous requirement to meet newly-imposed conditions for bioequivalence prior to receiving final approval for generic Focalin XR), CLLS +4.6% (announced it is eligible to receive an undisclosed payment under the terms of its collaboration agreement with Servier), IG +4.4% (FDA approval and commercial launch of Diclofenac Sodium, 1.5%; has already secured orders), TMUS +4% ( reports it generated 2.1 million total net customer additions), JUNO +3.3% ( Celgene (CELG) discloses 9.1 active stake in 13D filing; collaboration was announced on June 29), FIT +2.9% (cont vol post IPO), DEPO +2.2% (announced that the Patent Trial and Appeal Board has confirmed the patentability of each of the 25 claims subject to the inter partes review proceedings initiated by Purdue Pharma against two Depomed patents), MU +1.6% (appointed Trevor Schulze as Chief Information Officer), AZN +1.6% (AZN and EvoRx meet primary goal of the collaboration; AZN to continue the development of the lead candidates), CAG +0.9% (announced appointments of Bradley A. Alford and Timothy R. McLevish to the ConAgra Board of Directors; ConAgra and JANA have entered into a cooperation agreement)
Analyst comments: TUBE +6.9% (initiated with a Overweight at JP Morgan), MBLY +4.6% (upgraded to Outperform from Neutral at Robert W. Baird), CHGG +3.1% (initiated with a Outperform at Barrington Research), PUK +2.6% (added to Conviction Buy list at Goldman), SNN +2.3% (upgraded to Buy at Berenberg ), TRV +1.4% (upgraded to Buy from Neutral at BofA/Merrill),NI +0.9% (upgraded to Overweight from Neutral at JP Morgan
)
In reaction to earnings/guidance: PEP +2.3%, WBA +2.3%, AA +1.2%, COST +1.2%, (June SSS)
M&A news: MM +26.9% (TechCrunch report suggesting Verizon (VZ) might be considering acquisition of MM), YY +7.1% ("Going Private" Proposal for $68.50/ADS), AVP +1.7% (reports its divestiture of Liz Earle for £140 million in cash)
Select China related names showing strength: SHI +18.1%, AMCN +15.6%, WBAI +14.9%, NQ +14.5%, BZUN +12.4%, LTBR +11.5%, NOAH +11.5%, EJ +11.5%, JMEI +11%, CMCM +10.2%, YOKU +10.1%, XNET +9.9%, QIHU +9%, DANG +8.8%, VISN +8.1%, SINA +7.9%, SOHU +7.3%, JRJC +6.9%, WUBA +6.1%, JD +5.9%, CTRP +5.3%, LFC +4.4%, BIDU+3.4%
Select EU bank stocks trading higher: ING +4.1%, DB +3.1%, NBG +2.9%, HSBC +2.4%, CS +2.2%, BCS +2%
Select solar names showing early strength: SOL +8.7%, JASO +8.2%, JKS +6.9%, TSL +6.1%, YGE +5.3%
Other news: RMGN +35.3% (announces the signing of a multimillion agreement; Initial purchases under the award total $1.1 mln), IPCI +12.7% (announced the FDA rescinds previous requirement to meet newly-imposed conditions for bioequivalence prior to receiving final approval for generic Focalin XR), CLLS +4.6% (announced it is eligible to receive an undisclosed payment under the terms of its collaboration agreement with Servier), IG +4.4% (FDA approval and commercial launch of Diclofenac Sodium, 1.5%; has already secured orders), TMUS +4% ( reports it generated 2.1 million total net customer additions), JUNO +3.3% ( Celgene (CELG) discloses 9.1 active stake in 13D filing; collaboration was announced on June 29), FIT +2.9% (cont vol post IPO), DEPO +2.2% (announced that the Patent Trial and Appeal Board has confirmed the patentability of each of the 25 claims subject to the inter partes review proceedings initiated by Purdue Pharma against two Depomed patents), MU +1.6% (appointed Trevor Schulze as Chief Information Officer), AZN +1.6% (AZN and EvoRx meet primary goal of the collaboration; AZN to continue the development of the lead candidates), CAG +0.9% (announced appointments of Bradley A. Alford and Timothy R. McLevish to the ConAgra Board of Directors; ConAgra and JANA have entered into a cooperation agreement)
Analyst comments: TUBE +6.9% (initiated with a Overweight at JP Morgan), MBLY +4.6% (upgraded to Outperform from Neutral at Robert W. Baird), CHGG +3.1% (initiated with a Outperform at Barrington Research), PUK +2.6% (added to Conviction Buy list at Goldman), SNN +2.3% (upgraded to Buy at Berenberg ), TRV +1.4% (upgraded to Buy from Neutral at BofA/Merrill),NI +0.9% (upgraded to Overweight from Neutral at JP Morgan
)